ICI Rechallenge After irAEs: One in Five Face Grade 3 or Higher Toxicity
This cohort-restricted meta-analysis gives oncology pharmacists denominator-based estimates of recurrent and new toxicity, response, and discontinuation when immune checkpoint inhibitors (ICIs) are restarted after an immune-related adverse event (irAE).
📅 Journal publication: Nov 2026·Last updated: Nov 8, 2026
Rechallenging ICIs after adverse events shows high toxicity but promising disease control.
Managing immune checkpoint inhibitor (ICI) rechallenge after an immune-related adverse event (irAE) is critical for optimizing cancer treatment. Index-irAE recurrence was 25.4%, any post-rechallenge irAE was 44.2%, and grade ≥ 3 irAE was 19.8%. Disease control rate was 72.7%. The study highlights frequent toxicity upon ICI rechallenge, emphasizing the need for individualized risk-benefit evaluations. ICI rechallenge post-irAE shows significant toxicity but still offers disease control, requiring careful patient assessment.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chen X, Gao S, Zhang X, Cui R, Ma C, Yu X, Li S
Citation:Chen X, Gao S, Zhang X, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events: A Systematic Review and Meta-Analysis. Cancer medicine. 2026;15(11). doi:10.1002/cam4.72450